Antigen-specific IgG and IgA, but not IgE, activate the effector functions of eosinophils in the presence of antigen

International Archives of Allergy and Immunology

Volumn 154, Issue 2, 2011, Pages 119-127

  Muraki, Masato ^a,c   Gleich, Gerald J ^a,b   Kita, Hirohito ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dansyl; Eosinophil granule proteins; Eosinophil derived neurotoxin; Eosinophils; Immunoglobulins; Superoxides

Indexed keywords

EOSINOPHIL PROTEIN X; HISTAMINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 5; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; EOSINOPHIL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIGEN-ANTIBODY COMPLEX; DANSYL COMPOUNDS; EOSINOPHIL-DERIVED NEUROTOXIN; EOSINOPHILS; EPITOPES; HISTAMINE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; SERUM ALBUMIN, BOVINE; STATISTICS, NONPARAMETRIC; SUPEROXIDES;

EID: 77956066937     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320226     Document Type: Article

References (40)

1. Prussin C, Metcalfe DD: 4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003; 111:S486-S494.
2. Kita H, Adolphson CR, Gleich GJ: Biology of eosinophils; in Adkinson NFJr, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER (eds): Middleton's Allergy Principles and Practice, ed 6. Philadelphia, Mosby, 2003, vol 1, pp 305-332.
3. Trivedi SG, Lloyd CM: Eosinophils in the pathogenesis of allergic airways disease. Cell Mol Life Sci. 2007; 64: 1269-1289.
4. Jacobsen EA, Ochkur SI, Lee NA, Lee JJ: Eosinophils and asthma. Curr Allergy Asthma Rep. 2007; 7: 18-26.
5. Pearlman DS: Pathophysiology of the inflammatory response. J Allergy Clin Immunol 1999; 104:S132-S137.
6. Gounni AS, Lamkhioued B, Ochiai K, Tanaka Y, Delaporte E, Capron A, Kinet JP, Capron M: High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994; 367: 183-186. (Pubitemid 24031700)
7. Kayaba H, Dombrowicz D, Woerly G, Papin JP, Loiseau S, Capron M: Human eosinophils and human high affinity IgE receptor transgenic mouse eosinophils express low levels of high affinity IgE receptor, but release IL-10 upon receptor activation. J Immunol 2001; 167: 995-1003.
8. Seminario MC, Saini SS, MacGlashan DW Jr, Bochner BS: Intracellular expression and release of Fc epsilon RI alpha by human eosinophils. J Immunol 1999; 162: 6893-6900.
9. Kita H, Kaneko M, Bartemes KR, Weiler DA, Schimming AW, Reed CE, Gleich GJ: Does IgE bind to and activate eosinophils from patients with allergy? J Immunol 1999; 162: 6901-6911.
10. Peebles RS Jr, Liu MC, Lichtenstein LM, Hamilton RG: IgA, IgG and IgM quantification in bronchoalveolar lavage fluids from allergic rhinitics, allergic asthmatics, and normal subjects by monoclonal antibodybased immunoenzymetric assays. J Immunol Methods. 1995; 179: 77-86.
11. Benson M, Reinholdt J, Cardell LO: Allergen- reactive antibodies are found in nasal fluids from patients with birch pollen-induced intermittent allergic rhinitis, but not in healthy controls. Allergy 2003; 58: 386-392.
12. Nahm DH, Kim HY, Park HS: Elevation of specific immunoglobulin A antibodies to both allergen and bacterial antigen in induced sputum from asthmatics. Eur Respir J 1998; 12: 540-545.
13. Kaneko M, Swanson MC, Gleich GJ, Kita H: Allergen-specific IgG1 and IgG3 through Fc gamma RII induce eosinophil degranulation. J Clin Invest 1995; 95: 2813-2821.
14. Monteiro RC, Hostoffer RW, Cooper MD, Bonner JR, Gartland GL, Kubagawa H: Definition of immunoglobulin A receptors on eosinophils and their enhanced expression in allergic individuals. J Clin Invest 1993; 92: 1681-1685.
15. Motegi Y, Kita H: Interaction with secretory component stimulates effector functions of human eosinophils but not of neutrophils. J Immunol 1998; 161: 4340-4346.
16. Morrison SL, Porter SB, Trinh KR, Wims LA, Denham J, Oi VT: Variable region domain exchange influences the functional properties of IgG. J Immunol 1998; 160: 2802-2898.
17. Gala FA, Morrison SL: V region carbohydrate and antibody expression. J Immunol 2004; 172: 5489-5494.
18. Horie S, Gleich GJ, Kita H: Cytokines directly induce degranulation and superoxide production from human eosinophils. J Allergy Clin Immunol 1996; 98: 371-381.
19. Bankers-Fulbright JL, Bartemes KR, Kephart GM, Kita H, O'Grady SM:β 2-Integrinmediated adhesion and intracellular Ca 2+ release in human eosinophils. J Membr Biol 2009; 228: 99-109.
20. Bankers-Fulbright JL, Kephart GM, Loegering DA, Bradford AL, Okada S, Kita H, Gleich GJ: Sulfonylureas inhibit cytokine-induced eosinophil survival and activation. J Immunol 1998; 160: 5546-5553.
21. Plager DA, Henke SA, Matsuwaki Y, Madaan A, Squillace DL, Dierkhising RA, Kita H: Pimecrolimus reduces eosinophil activation associated with calcium mobilization. Int Arch Allergy Immunol 2009; 149: 119-126.
22. Chen XM, Tanaka T, Kobayashi Y, Shigematsu H, Okumura K: Experimental glomerulonephritis induced by immune complexes of monoclonal antibodies produced by immunoglobulin class-switch variants. Lab Invest 1987; 57: 665-672.
23. Abu-Ghazaleh RI, Fujisawa T, Mestecky J, Kyle RA, Gleich GJ: IgA-induced eosinophil degranulation. J Immunol 1989; 142: 2393-2400.
24. Graziano RF, Looney RJ, Shen L, Fanger MW: FcγR-mediated killing by eosinophils. J Immunol 1989; 142: 230-235.
25. Hartnell A, Moqbel R, Walsh GM, Bradley B, Kay AB: Fcγand CD11/CD18 receptor expression on normal density and low density human eosinophils. Immunology 1990; 69: 264-270.
26. Weiler CR, Kita H, Hukee M, Gleich GJ: Eosinophil viability during immunoglobulininduced degranulation. J Leukoc Biol 1996; 60: 493-501.
27. Shin MH, Kita H, Park HY, Seoh JY: Cysteine protease secreted by Paragonimus westermani attenuates effector functions of human eosinophils stimulated with immunoglobulin G. Infect Immun 2001; 69: 1599-1604.
28. Bartemes KR, McKinney S, Gleich GJ, Kita H: Endogenous platelet-activating factor is critically involved in effector functions of eosinophils stimulated with IL-5 or IgG. J Immunol 1999; 162: 2982-1989.
29. Bracke M, van de Graaf E, Lammers JW, Coffer PJ, Koenderman L: In vivo priming of FcγR functioning on eosinophils of allergic asthmatics. J Leukoc Biol 2000; 68: 655-661.
30. Wines BD, Hogarth PM: IgA receptors in health and disease. Tissue Antigens 2006; 68: 103-114.
31. Bartemes KR, Cooper KM, Drain KL, Kita H: Secretory IgA induces antigen-independent eosinophil survival and cytokine production without inducing effector functions. J Allergy Clin Immunol 2005; 116: 827-835.
32. Decot V, Woerly G, Loyens M, Loiseau S, Quatannens B, Capron M, Dombrowicz D: Heterogeneity of expression of IgA receptors by human, mouse, and rat eosinophils. J Immunol 2005; 174: 628-635.
33. Pleass RJ, Lang ML, Kerr MA, Woof JM: IgA is a more potent inducer of NADPH oxidase activation and degranulation in blood eosinophils than IgE. Mol Immunol 2007; 44: 1401-1408.
34. Truong MJ, Gruart V, Liu FT, Prin L, Capron A, Capron M: IgE-binding molecules (Mac- 2/ε BP) expressed by human eosinophils. Implication in IgE-dependent eosinophil cytotoxicity. Eur J Immunol 1993; 23: 3230-3235.
35. Dehlink E, Fiebiger E: The role of the highaffinity IgE receptor, FcepsilonRI, in eosinophilic gastrointestinal diseases. Immunol Allergy Clin North Am 2009; 29: 159-170.
36. Walsh GM, Moqbel R, Nagakura T, Iikura Y, Kay AB: Enhancement of the expression of eosinophil IgE receptor (FcγR2) and its function by platelet-activating factor. J Lipid Mediat 1990; 2:S177-S186.
37. Ebisawa M, Schleimer RP, Bickel C, Bochner S: Phenotyping of purified human peripheral blood eosinophils using blind panel mAb; in Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silberstein R, Springer T, Tedder TF, Todd RF (ed): Leukocyte Typing V. New York, Oxford University Press, 1995, p 1036.
38. Valerius T, Repp R, Kalden JR, Platzer E: Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol 1990; 145: 2950-2958.
39. Hartnell A, Kay AB, Wardlaw AJ: IFN-γ induces expression of FcγRIII (CD16) on human eosinophils. J Immunol 1992; 148: 1471-1478.
40. Davoine F, Labonte I, Ferland C, Mazer B, Chakir J, Laviolette M: Role and modulation of CD16 expression on eosinophils by cytokines and immune complexes. Int Arch Allergy Immunol 2004; 134: 165-172.